XTL Biopharmaceutica Non Current Liabilities Total Over Time
| XTLB Stock | USD 1.88 0.05 2.73% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out XTL Biopharmaceutica Performance and XTL Biopharmaceutica Correlation. XTL |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Liabilities Total Analysis
Compare XTL Biopharmaceuticals and related stocks such as Benitec Biopharma, Xenetic Biosciences, and ProPhase Labs Non Current Liabilities Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BNTC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.4 K | 26.9 K | 35.3 K | 2.5 M | 213 K | 1.1 M | 559 K | 284 K | 38 K | 36.1 K |
| XBIO | 212.8 K | 212.8 K | 3.2 M | 3.3 M | 3.1 M | 3 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 27 K | 362.5 K | 287.4 K | 0.0 | 0.0 |
| PRPH | 100 K | 885 K | 300 K | 200 K | 100 K | 1.5 M | 3.6 M | 562 K | 643 K | 110 K | 14.6 M | 15.1 M | 7.9 M | 21.7 M | 22.8 M |
| BOSC | 100 K | 2.7 M | 2 M | 1.3 M | 383 K | 3.7 M | 2.9 M | 2.8 M | 2.2 M | 2.6 M | 2.2 M | 1.7 M | 2.8 M | 2.7 M | 2.6 M |
XTL Biopharmaceuticals and related stocks such as Benitec Biopharma, Xenetic Biosciences, and ProPhase Labs Non Current Liabilities Total description
My Equities
My Current Equities and Potential Positions
| XTL Biopharmaceuticals Ltd | XTLB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.88
Check out XTL Biopharmaceutica Performance and XTL Biopharmaceutica Correlation. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
XTL Biopharmaceutica technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.